This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Avantor Q1 Earnings & Revenues Beat Estimates, Margins Decline
by Zacks Equity Research
AVTR benefits from stable Q1 revenues and improving demand trends, though margin pressure and volume softness weigh on profitability.
DXCMNegative Net Change COONegative Net Change EHCNegative Net Change AVTRNo Net Change
earnings medical medical-devices
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
by Zacks Equity Research
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
CAHNegative Net Change GMEDNegative Net Change PAHCNegative Net Change GKOSNegative Net Change
earnings medical medical-devices
BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
by Zacks Equity Research
Baxter beats Q1 earnings and revenue estimates, sending shares higher despite declining profits and margin contraction.
BAXPositive Net Change CAHNegative Net Change GMEDNegative Net Change PAHCNegative Net Change
earnings medical medical-devices
Universal Logistics (ULH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ULHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CVS Q1 Earnings Preview: Health Services Likely to Lead Performance
by Zacks Equity Research
CVS Health heads into Q1 earnings results with Health Services growth expected to offset pressure in benefits, as revenues dip slightly and costs remain elevated.
CVSPositive Net Change AGENPositive Net Change SOLVPositive Net Change OKURNegative Net Change
earnings medical medical-devices
CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up
by Zacks Equity Research
CNMD tops Q1 estimates despite sales dip, lifts 2026 organic growth outlook as strategic shift sharpens focus on higher-growth segments.
CNMDNegative Net Change CAHNegative Net Change GMEDNegative Net Change PAHCNegative Net Change
medical medical-devices
GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines
by Zacks Equity Research
GE HealthCare misses Q1 EPS but tops revenue estimates as Imaging, AVS and PDx growth offset PCS weakness; shares slide due to margin pressure.
CAHNegative Net Change GMEDNegative Net Change PAHCNegative Net Change GEHCPositive Net Change
earnings medical medical-devices
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
by Zacks Equity Research
OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.
DXCMNegative Net Change COONegative Net Change OPKPositive Net Change EHCNegative Net Change
earnings medical medical-devices
Hims & Hers Expands Digital-First Access to Personalized Healthcare
by Debanjana Dey
HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.
TDOCPositive Net Change GDRXPositive Net Change HIMSPositive Net Change
medical medical-devices
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
by Indrajit Bandyopadhyay
Intuitive Surgical faces mixed international trends as China pressure and Japan delays cloud otherwise strong OUS growth outlook.
ISRGNegative Net Change DXCMNegative Net Change GKOSNegative Net Change
medical medical-devices